Richard Louis Elliott

This inventor holds 12 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Pfizer Corporation, Other. Active years: 2002-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Louis Elliott. Retrieved from https://idiyas.com/inventor/richard-louis-elliott

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12

% Patents Active = 41.7

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 2.1

ph-index = 5

Forward Citations = 142(Granted Patents)

Location History:

San Marcos, CA (US) (2003)
East Lyme, CT (US) (2002 - 2008)
Seattle, WA (US) (2012)

Company Filing History:

9 out of 4,488

Pfizer Corporation

patents

3 out of 834,570

Other

patents

Years Active: 2002-2012

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8318762 - Pyrazolospiroketone acetyl-CoA carboxylase inhibitors (2012-11-27),

2. 7358242 - Tetraazabenzo[e]azulene derivatives and analogs thereof (2008-04-15),

3. 7265104 - Tetraazabenzo[e]azulene derivatives and analogs thereof (2007-09-04),

4. 6949564 - NPY-5 antagonists (2005-09-27),

5. 6649759 - Neuropeptide Y antagonists (2003-11-18),

6. 6606962 - Horse feeder (2003-08-19),

7. 6566367 - Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines (2003-05-20),

8. 6515133 - Pharmaceutical compositions containing certain diarylimidazole derivatives (2003-02-04),

9. 6514966 - Compounds for the treatment of obesity (2003-02-04),

10. 6511984 - Neuropeptide Y antagonists (2003-01-28),

11. 6399631 - Carbazole neuropeptide Y5 antagonists (2002-06-04),

12. 6355635 - Compounds for the treatment of obesity (2002-03-12),

Title: The Innovative Journey of Richard Louis Elliott

Introduction

Richard Louis Elliott, an accomplished inventor based in East Lyme, Connecticut, has made significant contributions to the field of pharmaceuticals. With a total of 12 patents to his name, Elliott has focused on developing innovative compounds that address important medical conditions.

Latest Patents

Among his latest inventions, Elliott introduced "Pyrazolospiroketone acetyl-CoA carboxylase inhibitors." This invention encompasses compounds of Formula (1) or their pharmaceutically acceptable salts. The compounds are designed to inhibit the acetyl-CoA carboxylase enzyme(s), providing potential therapeutic options for treating various diseases, conditions, or disorders linked to this enzyme.

Another notable patent from Elliott is related to "Tetraazabenzo[e]azulene derivatives and analogs thereof." This invention centers on CCK-A agonists of Formula (I) and includes pharmaceutical compositions containing these compounds. They are particularly useful in the treatment of diabetes, showcasing Elliott’s commitment to addressing critical health challenges.

Career Highlights

Richard Louis Elliott has enjoyed a remarkable career, including significant tenures at Pfizer Corporation, where he contributed to groundbreaking research and development efforts. His work at such a renowned organization reflects his dedication to innovative pharmaceuticals and his expertise in the field.

Collaborations

Throughout his career, Elliott has collaborated with esteemed colleagues, including Marlys Hammond and Charles A. Blum. These professional interactions have likely enriched his research and significantly influenced his inventive processes.

Conclusion

Richard Louis Elliott's extensive patent portfolio and innovative spirit highlight his significant contributions to medical science. His focus on developing new therapies demonstrates a commitment to improving health outcomes and showcasing the transformative power of invention in the pharmaceutical industry.

Profile summary based on public USPTO records.